Reaction
Injection Site Cellulitis reporting signals
As of the last recalculation, Injection Site Cellulitis appears in 1,816 FAERS reports alongside 20 co-occurring drug terms. The strongest observed disproportionality signal is INTERFERON BETA-1B (PRR 68.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Interferon Beta-1B | 108 | 68.6 | 69.0 |
| Naltrexone | 107 | 42.2 | 42.4 |
| Interferon Beta-1A | 268 | 18.5 | 18.5 |
| Fremanezumab-Vfrm | 15 | 15.1 | 15.1 |
| Ixekizumab | 44 | 13.9 | 14.0 |
| Granisetron | 12 | 13.2 | 13.2 |
| Cabotegravir | 9 | 12.8 | 12.8 |
| Pegvaliase-Pqpz | 9 | 12.6 | 12.6 |
| Peginterferon Beta-1A | 14 | 12.3 | 12.3 |
| Buprenorphine | 85 | 11.0 | 11.0 |
| Asfotase Alfa | 8 | 9.2 | 9.2 |
| Glatiramer Acetate | 46 | 9.0 | 9.0 |
| Testosterone Cypionate | 7 | 9.0 | 9.0 |
| Paliperidone Palmitate | 24 | 8.6 | 8.7 |
| Inclisiran | 4 | 5.7 | 5.7 |
| Treprostinil | 54 | 5.1 | 5.1 |
| Lurasidone Hydrochloride | 8 | 4.4 | 4.4 |
| Galcanezumab-Gnlm | 10 | 3.7 | 3.7 |
| Romosozumab-Aqqg | 4 | 3.4 | 3.4 |
| Tirzepatide | 30 | 2.1 | 2.1 |